DAVENPORT 13F: Cuts The Cooper Companies (COO) Stake by $32M
A new regulatory filing shows Davenport reduced its holdings in The Cooper Companies, Inc. by 92.6% during the period.
Reviewed by automated data checks against the source filing. How we make and check alerts
DAVENPORT sold 571,488 shares from its stake in The Cooper Companies, Inc. ($COO), a 92.57% decrease, according to a 13F filing with the SEC dated October 14, 2026. It reported 45,902 shares worth $2.60 million at the end of the quarter.
Since the filing, $COO is up 5.6% to date (from the $54.88 close on Oct 14, 2026).
COO
The Cooper Companies, Inc.
Key Points
- Davenport reported cutting its stake in The Cooper Companies, Inc. (COO) by 571,488 shares, leaving it with 45,902 shares in a filing on October 14, 2026.
- The Cooper Companies recently reported trailing-twelve-month revenue of $4.24 billion and earnings of $2.91 per share.
- Several insiders added shares of the medical device maker, and analysts recently updated their views on the stock ahead of upcoming earnings.
Get $COO trade alerts by text
We text you when insiders, Congress or big funds trade $COO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated The Cooper Companies, Inc. alert may contain errors. Disclosures
In a filing on October 14, 2026, Davenport disclosed that it cut its stake in The Cooper Companies, Inc. (NasdaqGS: COO) by 571,488 shares. Note that 13F filings are backward-looking and reflect holdings as of the reported period, meaning they may not represent the investor's current position today.
Inside Davenport's The Cooper Companies Trade
Davenport reduced its position by 92.6%, going from 617,390 shares down to 45,902 shares. The remaining stake had a reported value of about $2.6 million at the end of the period.
Other Institutional Activity in The Cooper Companies
Other large funds also adjusted their portfolios around the medical device maker. Blackrock Inc. grew its holdings by -1588695 shares, ending with 15029453 shares worth about $870806486.0. Vanguard Capital Management LLC grew its holdings by 39430 shares, ending with 12758769 shares worth about $739243058.0. State Street Corporation grew its holdings by 124508 shares, ending with 8892643 shares worth about $515239723.0. Vanguard Portfolio Management LLC grew its holdings by -51455 shares, ending with 8669690 shares worth about $502321826.0. T. Rowe Price Investment Management, Inc. grew its holdings by -1630874 shares, ending with 7429535 shares worth about $430467247.0.
The Cooper Companies, Inc. Stock Up 0.6%
The stock recently traded around $57.72. Shares sit below key moving averages and well off their 52-week high.
Recent Earnings
The Cooper Companies operates through its CooperVision and CooperSurgical divisions, developing vision care products and medical devices. The company brought in $4.24 billion in trailing-twelve-month revenue with earnings of $2.91 per share. Its net profit margin stands at 13.5% with a return on equity of 6.8%. Management's next quarterly earnings update is scheduled for December 10, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
7 target cuts vs 0 raises.
-
EPS & revenue
EPS beat estimates by 9.3%. Revenue beat estimates by 1.6%.
-
Profit surprise
EBITDA missed sharply. Operating income missed sharply.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
7 target cuts.
-
Earnings quality
Operating margin down 21.3 points. Positive free cash flow.
Earnings Call Summary
Cooper beat earnings at $1.21 per share versus $1.10 expected, with revenue of $1.08 billion topping the $1.064 billion consensus. However, the company took a large $271.6 million charge to settle litigation tied to a 2023 embryo culture media recall. The company is running a strategic review of its surgery business and has received multiple indications of interest, though no deal is imminent.
Guidance Cooper cut its full year sales forecast to about $4.28 billion to $4.32 billion, down from prior expectations. The company now expects organic growth of 3.5 percent to 4.5 percent instead of the prior range. Asia Pacific contact lens sales are declining because customers are shifting to glasses and online purchases, and Japan and China are softer than expected.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at The Cooper Companies, Inc.
Insiders have been active in the stock. Director Paul A Keel bought 4,701 shares on September 11, 2026, at $53.18 for a total of $250,000. Director Walter M Rosebrough Jr bought 10,000 shares on September 14, 2026, valued at $541,640. Director Lawrence Erik Kurzius bought 10,000 shares on September 14, 2026, at $53.92 for $539,150, and followed up by purchasing another 10,000 shares on September 16, 2026, at $54.93 for $549,320.
Analysts Set New Price Targets
Wall Street firms have updated their outlooks on the healthcare firm. William Blair downgraded the stock to Market Perform on September 10, 2026. Wells Fargo maintained an Equal-Weight view and adjusted its target to $61 on September 10, 2026. Mizuho kept an Outperform rating with a $75 target on September 11, 2026. Needham reiterated a Buy rating with a $73 target on September 15, 2026. Barclays initiated coverage with an Equal-Weight rating and a $60 target on October 7, 2026. Overall, the stock carries a consensus hold rating with a mean target price of $65.80.
About The Cooper Companies
Headquartered in San Ramon, California, The Cooper Companies, Inc. makes contact lenses and surgical equipment used by healthcare providers worldwide. Its CooperVision segment focuses on specialty lenses for astigmatism and presbyopia, while CooperSurgical serves clinician needs in medical fields. Institutional portfolio shifts like Davenport's filing highlight how major investors reallocate capital within the healthcare sector.
Bottom Line
Investors will look toward the upcoming earnings release on December 12, 2026, for further updates on revenue growth and profitability. This filing reflects past portfolio adjustments and should be viewed alongside ongoing market developments.
Related Filing Alerts
Source: DAVENPORT's 13F filing on $COO (Oct 14, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: DAVENPORT 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts